>>12257515You're not too far off, p52 or related mutations are present in 80-some percent of human cancers. Since p52 is central to the process of recognizing DNA damage and initiating apoptosis, it's an important hurdle to overcome. I think there are like 16 domains of p52 (can't remember off the top of my head) and generally cancer benefits from mutations in ALL the domains, because even a less-functional p52 is pretty kill for cancers.
Cyclin-related issues are also very common to allow for increased mitogenic capability, but this is just as often due to a constitutively active mitogenic pathway (MAPK is common, so are APC disruptions like GSK3 being inactive or sequestered or downregulated, resulting in higher beta-catenin signaling) as it is to mutations or issues with actual cyclins (in fact this is less common overall). Also, we're just talking cell cycle control and DNA repair - don't forget cancer tends to loop glycolysis like a motherfucker and the arguably most important aspect of cancer - metastasis - is related to a host of factors like epithelial-to-mesenchymal transition, ability to bind platelets and survive sheer forces of bloodstream, ability to perform intravasation to begin with.... and again, now we're still only talking about the cancer cells themselves, ignoring the influence and "recruitment" of noncancer cells - CAFs, M2 macrophages, Tregs, angiogenesis.. nothing exists in a vaccuum. considering the extent of your studies so far, you've got the right idea as to what you might expect.
More to OP - if somebody "cured cancer", the large pharmaceutical companies would make them an offer they can't refuse, and probably rather than "hide the cure" they would just charge an exorbitant amount for licensing of the treatment
